MIF在非酒精性脂肪性肝病中的研究进展
Research Progress of MIF in Nonalcoholic Fatty Liver Disease
摘要: 随着代谢性疾病患病率逐渐的增加，非酒精性脂肪性肝病(NAFLD)正在成为肝脏相关疾病和死亡的主要原因，目前NAFLD全球患病率约为30%，但目前还没有FDA批准用于治疗NAFLD的药物。NAFLD疾病的谱系从肝脏脂肪变性延伸到非酒精性脂肪性肝炎(NASH)。据统计大约20%的NAFLD患者可进展为NASH，从而进一步发展为肝纤维化、肝硬化或肝细胞癌(HCC)。继发于NASH的肝硬化已成为肝移植的第二大适应症，其患病率预计将逐年上升，并在未来超过所有其他移植适应症。因此，NAFLD已成为一个全球性的健康问题，造成了重大的社会经济负担。巨噬细胞迁移抑制因子(MIF)是一种多效性细胞因子，通过巨噬细胞对炎症的反应，抑制巨噬细胞的迁移，促进细胞因子的积累、增殖、活化和分泌，从而在炎症、自身免疫性疾病和肿瘤等疾病的发病机制中发挥关键作用。在过去的30年中，即使在肝病管理取得重大进展之后，全世界仍有数百万人患有急性或慢性肝病。越来越多的研究发现MIF在代谢相关性肝病中起着非常重要的作用。因此，本文旨在全面综述MIF作为多效性细胞因子在NAFLD中的作用、分子机制及临床证据，以期为今后的相关研究提供参考。
Abstract: Nonalcoholic fatty liver disease (NAFLD) is becoming the most common chronic liver disease world-wide, affecting 30% of the world’s population. Cirrhosis secondary to nonalcoholic steatohepatitis (NASH) has become the second leading indication for liver transplantation, and its prevalence is expected to increase annually and surpass all other transplant indications in the future. As a result, NAFLD has become a global health problem with a significant socioeconomic burden. Macrophage migrate on inhibitory factor (MIF) is a pleiotropic cytokine that plays a key role in the pathogenesis of diseases such as inflammation, autoimmune diseases, and tumors by inhibiting macrophage mi-gration and promoting cytokine accumulation, proliferation, activation, and secretion through macrophage response to inflammation. Over the past 30 years, millions of people around the world have suffered from acute or chronic liver disease, even after significant advances in liver disease management.
文章引用：阿依古扎丽·阿不力提浦, 霍梦含, 杜国利. MIF在非酒精性脂肪性肝病中的研究进展[J]. 临床医学进展, 2024, 14(2): 2483-2489. https://doi.org/10.12677/ACM.2024.142348

参考文献

[1] Han, S.K., Baik, S.K. and Kim, M.Y. (2023) Non-Alcoholic Fatty Liver Disease: Definition and Subtypes. Clinical and Molecular Hepatology, 29, S5-S16. [Google Scholar] [CrossRef] [PubMed]
[2] Rong, L., Zou, J., Ran, W., Qi, X., Chen, Y., Cui, H. and Guo, J, (2022) Advancements in the Treatment of Non-Alcoholic Fatty Liver Disease, (NAFLD). Frontiers in Endocrinology (Lausanne), 13, Article ID: 1087260. [Google Scholar] [CrossRef] [PubMed]
[3] Zhou, J., Zhou, F., Wang, W., Zhang, X.-J., Ji, Y.-X., Zhang, P., She, Z.-G., Zhu, L., Cai, J. and Li, H. (2020) Epidemiological Features of NAFLD from 1999 to 2018 in China. Hepa-tology, 71, 1851-1864. [Google Scholar] [CrossRef] [PubMed]
[4] Sodhi, M., Rezaeianzadeh, R., Kezouh, A. and Etminan, M. (2023) Risk of Gastrointestinal Adverse Events Associated with Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss. JAMA, 330, 1795-1797. [Google Scholar] [CrossRef] [PubMed]
[5] Friedman, S.L., Neuschwander-Tetri, B.A., Rinella, M. and Sanyal, A.J. (2018) Mechanisms of NAFLD Development and Therapeutic Strategies. Nature Medicine, 24, 908-922. [Google Scholar] [CrossRef] [PubMed]
[6] Vuppalanchi, R., Noureddin, M., Alkhouri, N. and Sanyal, A.J. (2021) Therapeutic Pipeline in Nonalcoholic Steatohepatitis. Nature Reviews Gastroenterology & Hepatology, 18, 373-392. [Google Scholar] [CrossRef] [PubMed]
[7] Alkhouri, N., Herring, R., Kabler, H., Kayali, Z., Has-sanein, T., Kohli, A., Huss, R.S., Zhu, Y., Billin, A.N., Damgaard, L.H., Buchholtz, K., Kjær, M.S., Balendran, C., My-ers, R.P., Loomba, R. and Noureddin, M. (2022) Safety and Efficacy of Combination Therapy with Semaglutide, Ci-lofexor and Firsocostat in Patients with Non-Alcoholic Steatohepatitis: A Randomised, Open-Label Phase II Trial. Jour-nal of Hepatology, 77, 607-618. [Google Scholar] [CrossRef] [PubMed]
[8] Song, S., Xiao, Z., Dekker, F.J., Poelarends, G.J. and Melgert, B.N. (2022) Macrophage Migration Inhibitory Factor Family Proteins Are Multitasking Cytokines in Tissue Injury. Cellular and Molecular Life Sciences, 79, Article No. 105. [Google Scholar] [CrossRef] [PubMed]
[9] Leng, L., Metz, C.N., Fang, Y., Xu, J., Donnelly, S., Baugh, J., Delohery, T., Chen, Y., Mitchell, R.A. and Bucala, R. (2003) MIF Sig-nal Transduction Initiated by Binding to CD74. Journal of Experimental Medicine, 197, 1467-1476. [Google Scholar] [CrossRef] [PubMed]
[10] Barnes, M.A., McMullen, M.R., Roychowdhury, S., Pisano, S.G., Liu, X., Stavitsky, A.B., Bucala, R. and Nagy, L.E. (2013) Macrophage Migration Inhibitory Factor Contributes to Etha-nol-Induced Liver Injury by Mediating Cell Injury, Steatohepatitis, and Steatosis. Hepatology, 57, 1980-1991. [Google Scholar] [CrossRef] [PubMed]
[11] Bernhagen, J., Krohn, R., Lue, H., Gregory, J.L., Zernecke, A., Koenen, R.R., Dewor, M., Georgiev, I., Schober, A., Leng, L., Kooistra, T., Fingerle-Rowson, G., Ghezzi, P., Kleemann, R., McColl, S.R., Bucala, R., Hickey, M.J. and Weber, C. (2007) MIF Is a Noncognate Ligand of CXC Chemokine Recep-tors in Inflammatory and Atherogenic Cell Recruitment. Nature Medicine, 13, 587-596. [Google Scholar] [CrossRef] [PubMed]
[12] Su, H., Na, N., Zhang, X. and Zhao, Y. (2017) The Biological Function and Significance of CD74 in Immune Diseases. Inflammation Research, 66, 209-216. [Google Scholar] [CrossRef] [PubMed]
[13] Lue, H., Thiele, M., Franz, J., Dahl, E., Speckgens, S., Leng, L., Fingerle-Rowson, G., Bucala, R., Lüscher, B. and Bernhagen, J. (2007) Macrophage Migration Inhibitory Factor, (MIF) Promotes Cell Survival by Activation of the Akt Pathway and Role for CSN5/JAB1 in the Control of Autocrine MIF Activity. Oncogene, 26, 5046-5059. [Google Scholar] [CrossRef] [PubMed]
[14] Shi, X., Leng, L., Wang, T., Wang, W., Du, X., Li, J., McDonald, C., Chen, Z., Murphy, J.W., Lolis, E., Noble, P., Knudson, W. and Bucala, R. (2006) CD44 Is the Signaling Component of the Macrophage Migration Inhibitory Factor-CD74 Receptor Complex. Immunity, 25, 595-606. [Google Scholar] [CrossRef] [PubMed]
[15] Mitchell, R.A., Metz, C.N., Peng, T. and Bucala, R. (1999) Sustained Mitogen-Activated Protein Kinase, (MAPK) and Cytoplasmic Phospholipase A2 Activation by Macrophage Migration Inhibitory Factor, (MIF). Regulatory Role in Cell Proliferation and Glucocorticoid Action. Journal of Biologi-cal Chemistry, 274, 18100-18106. [Google Scholar] [CrossRef] [PubMed]
[16] Mitchell, R.A., Liao, H., Chesney, J., Fingerle-Rowson, G., Baugh, J., David, J. and Bucala, R. (2002) Macrophage Migration Inhibitory Factor, (MIF) Sustains Macrophage Proinflamma-tory Function by Inhibiting P53: Regulatory Role in the Innate Immune Response. Proceedings of the National Academy of Sciences of the United States of America, 99, 345-350. [Google Scholar] [CrossRef] [PubMed]
[17] Bach, J.-P., Rinn, B., Meyer, B., Dodel, R. and Bacher, M. (2008) Role of MIF in Inflammation and Tumorigenesis. Oncology, 75, 127-133. [Google Scholar] [CrossRef] [PubMed]
[18] Weber, C., Kraemer, S., Drechsler, M., Lue, H., Koenen, R.R., Kapurniotu, A., Zernecke, A. and Bernhagen, J. (2008) Structural Determinants of MIF Functions in CXCR2-Mediated Inflammatory and Atherogenic Leukocyte Recruitment. Proceedings of the National Academy of Sciences of the United States of America, 105, 16278-16283. [Google Scholar] [CrossRef] [PubMed]
[19] Morrison, M.C. and Kleemann, R. (2015) Role of Macrophage Mi-gration Inhibitory Factor in Obesity, Insulin Resistance, Type 2 Diabetes, and Associated Hepatic Co-Morbidities: A Comprehensive Review of Human and Rodent Studies. Frontiers in Immunology, 6, Article No. 308. [Google Scholar] [CrossRef] [PubMed]
[20] Chan, P.-C., Wu, T.-N., Chen, Y.-C., Lu, C.-H., Wabitsch, M., Tian, Y.-F. and Hsieh, P.-S. (2018) Targetted Inhibition of CD74 Attenuates Adipose COX-2-MIF-Mediated M1 Mac-rophage Polarization and Retards Obesity-Related Adipose Tissue Inflammation and Insulin Resistance. Clinical Science (London), 132, 1581-1596. [Google Scholar] [CrossRef] 
[21] Finucane, O.M., Reynolds, C.M., McGillicuddy, F.C., Harford, K.A., Morrison, M., Baugh, J. and Roche, H.M. (2014) Macrophage Migration Inhibitory Factor Deficiency Ameliorates High-Fat Diet Induced Insulin Resistance in Mice with Reduced Adipose Inflammation and Hepatic Steatosis. PLOS ONE, 9, e113369. [Google Scholar] [CrossRef] [PubMed]
[22] Alvehus, M., Burén, J., Sjöström, M., Goedecke, J. and Olsson, T. (2010) The Human Visceral Fat Depot Has a Unique Inflammatory Profile. Obesity (Silver Spring), 18, 879-883. [Google Scholar] [CrossRef] [PubMed]
[23] Verschuren, L., Kooistra, T., Bernhagen, J., Voshol, P.J., Ouwens, D.M., Van Erk, M., De Vries-Van, Der Weij, J., Leng, L., Van Bockel, J.H., Van Dijk, K.W., Fingerle-Rowson, G., Bucala, R. and Kleemann, R. (2009) MIF Deficiency Reduces Chronic Inflammation in White Adipose Tissue and Impairs the De-velopment of Insulin Resistance, Glucose Intolerance, and Associated Atherosclerotic Disease. Circulation Research, 105, 99-107. [Google Scholar] [CrossRef] 
[24] Conine, S.J. and Cross, J.V. (2014) MIF Deficiency Does Not Alter Glucose Homeostasis or Adipose Tissue Inflammatory Cell Infiltrates During Diet-Induced Obesity. Obesity (Silver Spring), 22, 418-425. [Google Scholar] [CrossRef] [PubMed]
[25] Akyildiz, M., Gunsar, F., Nart, D., Sahin, O., Yilmaz, F., Akay, S., Ersoz, G., Karasu, Z., Ilter, T., Batur, Y., Berdeli, A. and Akarca, U. (2010) Macrophage Migration Inhibitory Factor Expres-sion and MIF Gene-173 G/C Polymorphism in Nonalcoholic Fatty Liver Disease. European Journal of Gastroenterolo-gy & Hepatology, 22, 192-198. [Google Scholar] [CrossRef] 
[26] Moon, H.Y., Song, P., Choi, C.S., Ryu, S.H. and Suh, P.-G. (2013) Involvement of Exercise-Induced Macrophage Migration Inhibitory Factor in the Prevention of Fatty Liver Disease. Journal of Endocrinology, 218, 339-348. [Google Scholar] [CrossRef] 
[27] Hu, M., Zhang, D., Xu, H., Zhang, Y., Shi, H., Huang, X., Wang, X., Wu, Y. and Qi, Z. (2021) Salidroside Activates the AMP-Activated Protein Kinase Pathway to Suppress Nonalcoholic Steatohepatitis in Mice. Hepatology, 74, 3056- 3073. [Google Scholar] [CrossRef] [PubMed]
[28] You, B., Dun, Y., Fu, S., Qi, D., Zhang, W., Liu, Y., Qiu, L., Xie, M. and Liu, S. (2021) The Treatment of Rhodiola Mimics Exercise to Resist High-Fat Diet-Induced Muscle Dysfunction via Sirtuin1-Dependent Mechanisms. Frontiers in Pharmacology, 12, Arti-cle ID: 646489. [Google Scholar] [CrossRef] [PubMed]
[29] Heinrichs, D., Brandt, E.F., Fischer, P., Köhncke, J., Wirtz, T.H., Guldiken, N., Djudjaj, S., Boor, P., Kroy, D., Weiskirchen, R., Bucala, R., Wasmuth, H.E., Strnad, P., Trautwein, C., Bernhagen, J. and Berres, M.-L. (2021) Unexpected Pro-Fibrotic Effect of MIF in Non-Alcoholic Steato-hepatitis Is Linked to a Shift in NKT Cell Populations. Cells, 10, Article No. 252. [Google Scholar] [CrossRef] [PubMed]
[30] Park, O., Jeong, W.-I., Wang, L., Wang, H., Lian, Z.-X., Gershwin, M.E. and Gao, B. (2009) Diverse Roles of Invariant Natural Killer T Cells in Liver Injury and Fibrosis Induced by Car-bon Tetrachloride. Hepatology, 49, 1683-1694. [Google Scholar] [CrossRef] [PubMed]
[31] Syn, W.-K., Agboola, K.M., Swiderska, M., Michelotti, G.A., Liaskou, E., Pang, H., Xie, G., Philips, G., Chan, I.S., Karaca, G.F., Pereira, T.A., Chen, Y., Mi, Z., Kuo, P.C., Choi, S.S., Guy, C.D., Abdelmalek, M.F. and Diehl, A.M. (2012) NKT-Associated Hedgehog and Osteopontin Drive Fibrogenesis in Non-Alcoholic Fatty Liver Disease. Gut, 61, 1323-1329. [Google Scholar] [CrossRef] [PubMed]
[32] Kumar, V. (2013) NKT-Cell Subsets: Promoters and Protectors in Inflammatory Liver Disease. Journal of Hepatology, 59, 618-620. [Google Scholar] [CrossRef] [PubMed]
[33] Heinrichs, D., Berres, M.-L., Coeuru, M., Knauel, M., Nellen, A., Fischer, P., Philippeit, C., Bucala, R., Trautwein, C., Wasmuth, H.E. and Bernhagen, J. (2014) Protective Role of Macrophage Migration Inhibitory Factor in Nonalcoholic Steatohepatitis. The FASEB Journal, 28, 5136-5147. [Google Scholar] [CrossRef] [PubMed]
[34] Heinrichs, D., Knauel, M., Offermanns, C., Berres, M.-L., Nellen, A., Leng, L., Schmitz, P., Bucala, R., Trautwein, C., Weber, C., Bernhagen, J. and Wasmuth, H.E. (2011) Macrophage Mi-gration Inhibitory Factor, (MIF) Exerts Antifibrotic Effects in Experimental Liver Fibrosis via CD74. Proceedings of the National Academy of Sciences of the United States of America, 108, 17444-17449. [Google Scholar] [CrossRef] [PubMed]
[35] Thuy, L.T.T. and Kawada, N. (2012) Antifibrotic Role of Macro-phage Migration Inhibitory Factor: Discovery of an Unexpected Function. Hepatology, 55, 1295-1297. [Google Scholar] [CrossRef] [PubMed]

为你推荐